Our pipeline features nine therapeutics to treat Alzheimer’s disease and offers unprecedented benefits:
1. Definitive targets – antigens that cause Alzheimer’s
2. Definitive biomarkers – measure the antigens of Alzheimer’s
3. Inherently optimized- to guide the clinical trials
RecruitmentAcuurately identify responsive subjects
RetrospectiveRetrospectively stratify subjects of past clinical trials
LongitudinalLongitudinally monitor subject’s drug response during clinical trials to develop Companion diagnostics
ProspectiveProspectively recruitment subjects for future clinical trials
Definitively identify disease-causing pathogenic antigens.
“Epitope-Gene ID” mapping to link immunotherapeutics.
For partnering inquiries, please contact: firstname.lastname@example.org
Anven Biosciences, Inc.